DE69706566D1 - Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit - Google Patents

Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit

Info

Publication number
DE69706566D1
DE69706566D1 DE69706566T DE69706566T DE69706566D1 DE 69706566 D1 DE69706566 D1 DE 69706566D1 DE 69706566 T DE69706566 T DE 69706566T DE 69706566 T DE69706566 T DE 69706566T DE 69706566 D1 DE69706566 D1 DE 69706566D1
Authority
DE
Germany
Prior art keywords
clioquinol
imager
chelate
disease
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69706566T
Other languages
English (en)
Other versions
DE69706566T2 (de
Inventor
Nikolas Gerolymatos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PN Gerolymatos SA
Original Assignee
PN Gerolymatos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PN Gerolymatos SA filed Critical PN Gerolymatos SA
Publication of DE69706566D1 publication Critical patent/DE69706566D1/de
Application granted granted Critical
Publication of DE69706566T2 publication Critical patent/DE69706566T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69706566T 1996-08-13 1997-08-08 Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit Expired - Lifetime DE69706566T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR96100286 1996-08-13
PCT/IB1997/000983 WO1998006403A1 (en) 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69706566D1 true DE69706566D1 (de) 2001-10-11
DE69706566T2 DE69706566T2 (de) 2002-07-11

Family

ID=10942479

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69706566T Expired - Lifetime DE69706566T2 (de) 1996-08-13 1997-08-08 Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit

Country Status (26)

Country Link
US (1) US6001852A (de)
EP (1) EP0959888B1 (de)
JP (1) JP2000516606A (de)
KR (1) KR100489969B1 (de)
CN (1) CN1114407C (de)
AT (1) ATE205086T1 (de)
AU (1) AU720643B2 (de)
BR (1) BR9711194A (de)
CA (1) CA2264097C (de)
CZ (2) CZ295118B6 (de)
DE (1) DE69706566T2 (de)
DK (1) DK0959888T3 (de)
ES (1) ES2162319T3 (de)
HK (1) HK1022437A1 (de)
HU (1) HUP9903906A3 (de)
IL (1) IL128416A (de)
IS (1) IS1907B (de)
NO (1) NO316768B1 (de)
NZ (1) NZ334124A (de)
PL (1) PL188838B1 (de)
PT (1) PT959888E (de)
RU (1) RU2193406C2 (de)
SI (1) SI0959888T1 (de)
SK (1) SK283117B6 (de)
TR (1) TR199900293T2 (de)
WO (1) WO1998006403A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
CA2301706C (en) 1997-08-21 2005-10-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
JP2001521002A (ja) * 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク. 脳の代謝機能不全のための栄養補充剤
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
ATE285235T1 (de) 1999-01-07 2005-01-15 Gerolymatos P N Sa Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
US6692234B2 (en) 1999-03-22 2004-02-17 Water Management Systems Pump system with vacuum source
US20040054182A1 (en) * 2000-02-09 2004-03-18 Hideo Kato 1h-imidazopyridine derivatives
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
KR101122782B1 (ko) 2002-10-04 2012-04-12 프라나 바이오테크놀로지 리미티드 신경 활성 화합물
US20080063599A1 (en) * 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CN1791408A (zh) * 2003-04-03 2006-06-21 普拉纳生物技术有限公司 神经系统疾病的治疗
WO2005049026A1 (en) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd Method and composition for treatment or prophylaxis of amyloidosis disorders
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
TWI319708B (en) * 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
RU2442793C2 (ru) * 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CA2683756A1 (en) 2006-04-14 2007-10-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration(amd)
PT2468770T (pt) * 2006-07-14 2018-03-09 Genentech Inc Anticorpo humanizado contra beta-amiloide
SG173385A1 (en) * 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RU2604181C2 (ru) 2007-10-05 2016-12-10 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
EP2981525A4 (de) * 2013-04-02 2016-12-21 Annji Pharm Co Ltd Multifunktionelle chinolinderivate als antineurodegenerative mittel
EP3135280B1 (de) 2014-04-24 2023-09-20 Omoidesouzou Co. Ltd. Tranilast zur behandlung von kutaner amyloidose
KR20160057500A (ko) * 2014-11-05 2016-05-24 아카데미아 시니카 클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174899A (en) * 1960-12-30 1965-03-23 Ciba Geigy Corp Composition for the management of post antibiotic enteritis
US3178343A (en) * 1962-11-27 1965-04-13 Ciba Geigy Corp Pharmaceutical compositions and method of using same
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE3932338A1 (de) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Verfahren zur praeventiven therapie von morbus alzheimer
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
GB9108080D0 (en) * 1991-04-15 1991-06-05 Smithkline Beecham Plc Pharmaceutical composition
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
CA2123211C (en) * 1991-11-12 2008-09-16 Colin L. Masters A method for assaying and treating alzheimer's disease
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU1831195A (en) * 1994-01-13 1995-08-01 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AU6580494A (en) * 1994-05-11 1995-12-05 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture

Also Published As

Publication number Publication date
JP2000516606A (ja) 2000-12-12
PL188838B1 (pl) 2005-04-29
NO990595L (no) 1999-04-12
CA2264097C (en) 2007-11-27
HUP9903906A2 (hu) 2000-04-28
WO1998006403A1 (en) 1998-02-19
TR199900293T2 (xx) 1999-06-21
CZ295118B6 (cs) 2005-05-18
CN1230115A (zh) 1999-09-29
SI0959888T1 (en) 2002-10-31
NZ334124A (en) 2000-10-27
DK0959888T3 (da) 2001-11-05
SK17999A3 (en) 1999-09-10
CN1114407C (zh) 2003-07-16
IS4972A (is) 1999-02-10
SK283117B6 (sk) 2003-02-04
NO316768B1 (no) 1999-04-12
IL128416A0 (en) 2000-01-31
HK1022437A1 (en) 2000-08-11
RU2193406C2 (ru) 2002-11-27
CZ48499A3 (cs) 1999-07-14
IL128416A (en) 2004-06-01
PL331822A1 (en) 1999-08-02
EP0959888A1 (de) 1999-12-01
ES2162319T3 (es) 2001-12-16
CA2264097A1 (en) 1998-02-19
AU720643B2 (en) 2000-06-08
AU3632497A (en) 1998-03-06
BR9711194A (pt) 2000-01-11
CZ292411B6 (cs) 2003-09-17
NO990595D0 (no) 1999-02-09
PT959888E (pt) 2002-02-28
KR20000029958A (ko) 2000-05-25
KR100489969B1 (ko) 2005-05-17
EP0959888B1 (de) 2001-09-05
ATE205086T1 (de) 2001-09-15
HUP9903906A3 (en) 2001-01-29
DE69706566T2 (de) 2002-07-11
US6001852A (en) 1999-12-14
IS1907B (is) 2003-12-16

Similar Documents

Publication Publication Date Title
DE69706566D1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
DE69424777T2 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE237610T1 (de) Substituierte dimere carboxamid-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
ATE281162T1 (de) Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose
GB9103764D0 (en) Compositions
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
GEP20032914B (en) Derivatives of 1,3,4-Oxadiazolone
NO20000771D0 (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE189385T1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition